Revenue Growth (YoY and Sequential)
Q1 2026 revenue of $1.6M, up 5% year-over-year and up 67% sequentially versus Q4 2025, demonstrating strong quarter-to-quarter momentum.
Applicator Sales Surge
Applicator sales in Q1 2026 exceeded total applicator sales for all of 2025, representing a 139% year-over-year increase, indicating rapid adoption of the consumable/razor-blade model.
BIT Solution Growth
BIT Solution (consumables) sales have grown ~21% annually since 2024 and remained above 2025 levels in Q1 2026, supporting the move toward higher recurring-margin revenue.
Operating Expense Reduction and Improved Operating Cash Flow
Total operating expenses declined 15% versus Q1 2025. The company generated positive operating cash flow of $296K in Q1 2026, an improvement of $572K versus the same period last year.
Backlog and Pipeline Expansion
Backlog grew from $1.6M at year-end 2025 to $2.2M at the end of Q1 2026 (a $0.5M increase). Management reports an integration pipeline of $4M across 14 customers and a broader full-company pipeline of $22M–$33M, with ~$9M categorized as active/approved for potential purchase this year.
Large Recurring Customer Contract
TOMI received 440,000 annual purchase orders for recurring decontamination services from a leading global medical technology company for quarterly professional IHP services, supporting high-margin, repeatable revenue.
Regulatory and Geographic Approvals
Regulatory progress includes U.K. Health & Safety Executive authorization (Great Britain & Northern Ireland), Dutch product authorization (first EU member state approval), and notifications of approvals in Germany, Belgium, Denmark and Hungary—facilitating broader EU market access.
Strategic Commercial Wins and Case Studies
Notable Q1 commercial traction: sale/installation of a SteraMist hybrid at a private East Coast research university (follow-on award), custom engineered system sale in the U.K. integrated into Total Clean Air's platform (Total Clean Air named preferred European partner), and food-safety case study showing up to 95% reduction in sanitization testing costs for an egg manufacturer.
Strategic LOI to Merge with Carbonium Core
Executed a nonbinding LOI to merge with Carbonium Core (nuclear-grade graphite producer). Proposed terms: Carbonium becomes a TOMI subsidiary; former Carbonium holders to receive 19.99% of TOMI common stock pre-transaction plus convertible preferred implying an enterprise valuation of $120M. Management expects to pursue definitive agreements and due diligence.